
NYSE:MDT
This summary was created by AI, based on 2 opinions in the last 12 months.
Medtronic Inc (MDT-N) has garnered a mix of opinions from experts. One expert sees the company benefiting from advancements in AI technologies, suggesting that boomers continuing to operate in the market serves as a tailwind for growth. Another expert expresses a more cautious outlook, highlighting that while MDT is currently experiencing a positive short- to medium-term phase and is positioned to compete strongly against peers like Boston Scientific, it may lack the research and development prowess to sustain its leadership over the long term. Despite being diversified in its product offerings, which is a strength compared to competitors focused solely on specific device categories, there are concerns about MDT's market position. Upcoming product launches and a perceived undervaluation, with the stock's price-to-earnings ratio being attractive, may support the stock for the next 12-18 months; however, the long-term outlook remains uncertain.
They have struggled over the most recent years after being a darling. There is the question of how healthcare will be paid for in the US. Device companies have the hardest headwinds. They are also in a very competitive area. It is not expensive and is a perfectly good way to be in the health care area. Their struggles may mean they have more upside potential if the healthcare sector improves.
This has everything you can think of that is tools related, from your head all the way down to your toes; cardiovascular, stent. The dominant player in medical technologies. Trading at 17X next year’s earnings. Had a hiccup last quarter, but all they had to do was show that things were back on track. He likes this.
He likes healthcare “devices”, because it is the area that is least likely to be attacked by a government. They are somewhat less regulated from a price standpoint. This company has very strong market share in rhythm devices. Earnings for the year should be up about 7% over last year, but should accelerate up to about 11% next year. It has consolidated between $80 and $90 going back to June. Sitting at around the 150 day moving average, so technically is in a good spot. You should see earnings accelerate going forward, which is what he cares about.
A medical device business, one of the largest in the world. A very diverse product line. Valuation at about 18X earnings, the high end of the range, but medical devices are trading at a premium to Pharma. He sees single digit revenue growth and double digit earnings growth, and expects some real growth to come out of things like aortic valve replacement. Dividend yield of 2.07%.
A healthcare company, but not a pharmaceutical company. They are very big in cardiovascular and diabetes. Growing their top line at roughly 5%-10% per annum, and the bottom line closer to 12%-13% for the foreseeable future for the next 4-5 years. They are in the right place at the right time, and are likely to return about $1 billion a year to the shareholders for the next few years. They are committed to increasing their dividends. Dividend yield of 1.98%.